Iridex announced that in the second quarter of 2018 it shipped the 1,000th unit of its »Cyclo G6 Laser System, which utilizes the company’s proprietary MicroPulse technology for the treatment of glaucoma. Dr. Ryo Taniguchi, of the Taniguchi Eye Clinic in Japan, Kyoshu Saga Prefecture, was the recipient of the 1,000th system.
“MicroPulse Laser therapy is a new and very promising technology in Japan, providing an effective and non-incisional treatment for glaucoma patients with a range of stages of the disease,” Makoto Aihara, MD, PhD, Professor and Chair, University of Tokyo, said in a company news release. “The earlier clinical research performed in US, Europe and Asia showed that MicroPulse is safe and effective in IOP reduction and medication use decrease, and my clinical findings confirm the previous studies’ results. As one of the first sites in Japan to use the Cyclo G6 for glaucoma treatment, we have seen significant benefits. Even patients with previous intraocular surgeries experienced positive results.”
The Cyclo G6 system is supported by a growing body of clinical evidence and extensive validation in the field for the treatment of glaucoma, according to Iridex. Physicians worldwide have adopted the Cyclo G6 because it is safe, minimally invasive, non-incisional, repeatable, and durable. Moreover, the Cyclo G6 provides physicians and the health care system a cost-effective solution for the treatment of glaucoma across the full continuum of care – from early to late stage glaucoma. More than 80,000 patients worldwide have been treated with the Cyclo G6 system.
“In my opinion, MicroPulse Laser therapy shifts the paradigm of glaucoma treatments in Japan. It provides a new choice for a safe, effective, and non-incisional treatment on various glaucoma patients with mild, moderate, and late stage disease. The MicroPulse procedure can be performed on a wide variety of patients not responding to medications or not qualified for incisional surgeries. Recent industry meetings and clinical presentations of leading physicians using the MicroPulse procedure in the United States, Europe and Asia have demonstrated and proven that fact. My initial clinical experience with it confirms these findings,” commented Dr. Ryo Taniguchi.
“We are delighted to achieve this exciting milestone in the commercialization of our Cyclo G6 laser system, as it not only demonstrates the traction the platform is gaining worldwide, but highlights the progress we have made in transforming our business to delivering a compelling and proven treatment alternative for patients suffering from glaucoma,” said William Moore, Chief Executive Officer of Iridex.